This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sodium/glucose cotransporter
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page '''Sodium/glucose cotransporter'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
| - | + | ||
== Function == | == Function == | ||
Revision as of 07:34, 15 April 2024
| |||||||||||
References
- ↑ Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9. PMID:26125647 doi:10.1097/MNH.0000000000000152
- ↑ Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020 Oct 16;295(42):14379-14390. PMID:32796035 doi:10.1074/jbc.REV120.008387
- ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939
